archive-org.com » ORG » S » SCIENCEMAG.ORG

Total: 698

Choose link from "Titles, links and description words view":

Or switch to "Titles and links view".
  • Therapy for Fibrotic Diseases: Nearing the Starting Line | Science Translational Medicine
    of extracellular matrix molecules that make up scar tissue is a common feature of chronic tissue injury Pulmonary fibrosis renal fibrosis and hepatic cirrhosis are among the more common fibrotic diseases which in aggregate represent a huge unmet clinical need New appreciation of the common features of fibrosis that are conserved among tissues has led to a clearer understanding of how epithelial injury provokes dysregulation of cell differentiation signaling and protein secretion At the same time discovery of tissue specific features of fibrogenesis combined with insights about genetic regulation of fibrosis has laid the groundwork for biomarker discovery and validation and the rational identification of mechanism based antifibrotic drugs Together these advances herald an era of sustained focus on translating the biology of fibrosis into meaningful improvements in quality and length of life in patients with chronic fibrosing diseases Copyright 2013 American Association for the Advancement of Science View Full Text Science Translational Medicine Vol 5 Issue 167 09 January 2013 Table of Contents Article Tools Email Thank you for your interest in spreading the word about Science Translational Medicine NOTE We only request your email address so that the person you are recommending the page to knows that you wanted them to see it and that it is not junk mail We do not capture any email address Your Email Your Name Send To Enter multiple addresses on separate lines or separate them with commas You are going to email the following Therapy for Fibrotic Diseases Nearing the Starting Line Message Subject Your Name has forwarded a page to you from Science Translational Medicine Message Body Your Name thought you would like to see this page from the Science Translational Medicine web site Your Personal Message Send Message Download Powerpoint Print Save to my folders User Name Password Remember my user name password Submit Alerts Please log in to add an alert for this article Username Enter your Sciencemag org username Password Enter the password that accompanies your username Log in Request Permissions Citation tools Therapy for Fibrotic Diseases Nearing the Starting Line By Scott L Friedman Dean Sheppard Jeremy S Duffield Shelia Violette Science Translational Medicine 09 Jan 2013 167sr1 An emerging consensus indicates that fibrotic diseases in lung liver and kidney exhibit common underlying mechanisms which can be targeted therapeutically Citation Manager Formats BibTeX Bookends EasyBib EndNote tagged EndNote 8 xml Medlars Mendeley Papers RefWorks Tagged Ref Manager RIS Zotero Share Therapy for Fibrotic Diseases Nearing the Starting Line By Scott L Friedman Dean Sheppard Jeremy S Duffield Shelia Violette Science Translational Medicine 09 Jan 2013 167sr1 An emerging consensus indicates that fibrotic diseases in lung liver and kidney exhibit common underlying mechanisms which can be targeted therapeutically Permalink Copy Related Content Perspective The Gut Microbiome in Intestinal Fibrosis Environmental Protector or Provocateur Focus Autoimmune Attack Takes Your Breath Away Focus One integrin to rule them all Research Article Phenotypic assays identify azoramide as a small molecule modulator of the unfolded protein response with antidiabetic activity Research

    Original URL path: http://stm.sciencemag.org/content/5/167/167sr1 (2016-02-10)
    Open archived version from archive


  • Therapy for Fibrotic Diseases: Nearing the Starting Line | Science Translational Medicine
    your Sciencemag org username Password Enter the password that accompanies your username Forgot your username or password Log in Join Subscribe Purchase Article Activate Member Account Renew Subscription Recommend a subscription to your library Help for librarians Editor s Summary Fibrosis the accumulation of excess extracellular matrix in injured tissue is the final common pathway for numerous diseases including many of the lung liver kidney and skin This State of the Art Review outlines an emerging consensus that these diseases have many underlying features in common The authors further describe ongoing efforts to develop effective therapies including a discussion of obstacles to progress Copyright 2013 American Association for the Advancement of Science Science Translational Medicine Vol 5 Issue 167 09 January 2013 Table of Contents Article Tools Email Thank you for your interest in spreading the word about Science Translational Medicine NOTE We only request your email address so that the person you are recommending the page to knows that you wanted them to see it and that it is not junk mail We do not capture any email address Your Email Your Name Send To Enter multiple addresses on separate lines or separate them with commas You are going to email the following Therapy for Fibrotic Diseases Nearing the Starting Line Message Subject Your Name has forwarded a page to you from Science Translational Medicine Message Body Your Name thought you would like to see this page from the Science Translational Medicine web site Your Personal Message Send Message Download Powerpoint Print Save to my folders User Name Password Remember my user name password Submit Alerts Please log in to add an alert for this article Username Enter your Sciencemag org username Password Enter the password that accompanies your username Log in Request Permissions Citation tools Therapy for Fibrotic Diseases Nearing the Starting Line By Scott L Friedman Dean Sheppard Jeremy S Duffield Shelia Violette Science Translational Medicine 09 Jan 2013 167sr1 An emerging consensus indicates that fibrotic diseases in lung liver and kidney exhibit common underlying mechanisms which can be targeted therapeutically Citation Manager Formats BibTeX Bookends EasyBib EndNote tagged EndNote 8 xml Medlars Mendeley Papers RefWorks Tagged Ref Manager RIS Zotero Share Therapy for Fibrotic Diseases Nearing the Starting Line By Scott L Friedman Dean Sheppard Jeremy S Duffield Shelia Violette Science Translational Medicine 09 Jan 2013 167sr1 An emerging consensus indicates that fibrotic diseases in lung liver and kidney exhibit common underlying mechanisms which can be targeted therapeutically Permalink Copy Related Content Perspective The Gut Microbiome in Intestinal Fibrosis Environmental Protector or Provocateur Focus Autoimmune Attack Takes Your Breath Away Focus One integrin to rule them all Research Article Phenotypic assays identify azoramide as a small molecule modulator of the unfolded protein response with antidiabetic activity Research Articles Obesity dependent changes in interstitial ECM mechanics promote breast tumorigenesis Similar Articles in PubMed Google Scholar Cited By miR 1343 attenuates pathways of fibrosis by targeting the TGF beta receptors Coenzyme Q10 prevents hepatic fibrosis inflammation and oxidative

    Original URL path: http://stm.sciencemag.org/content/5/167/167sr1.editor-summary (2016-02-10)
    Open archived version from archive



  •